stockportfolio.pro
Envista Holdings Corporation (NVST)
Healthcare · Medical Instruments & Supplies · NYSE
Envista Holdings Corporation revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.81B | $2.84B | $2.28B | $1.93B | $2.51B | $2.57B | $2.57B | $2.51B | $2.72B |
| Gross profit | $1.62B | $1.60B | $1.35B | $1.05B | $1.43B | $1.47B | $1.44B | $1.37B | $1.49B |
| Net income | $301.10M | $230.70M | $217.60M | $33.30M | $340.50M | $243.10M | $-100.20M | $-1.12B | $47.00M |
| Net margin | 10.7% | 8.1% | 9.5% | 1.7% | 13.6% | 9.5% | -3.9% | -44.6% | 1.7% |
Source: Envista Holdings Corporation SEC filings (10-K).
What growth is priced into NVST stock?
At today's market cap of $3.93B, Envista Holdings Corporation is priced for free-cash-flow growth of about 5.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $230.40M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.5%/yr over the last five fiscal years and revenue 7.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 9 years of Envista Holdings Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NVST in your portfolio →
Envista Holdings Corporation financial history by metric
About Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Envista Holdings Corporation — frequently asked questions
What is Envista Holdings Corporation's revenue?
Envista Holdings Corporation (NVST) reported revenue of $2.72B for fiscal year 2025, up 8.3% from the prior year, according to its SEC filings.
Is Envista Holdings Corporation profitable?
Yes. NVST earned net income of $47.00M in fiscal 2025, a net margin of 1.7%.
What is NVST's P/E ratio?
Envista Holdings Corporation trades at a price-to-earnings ratio of about 58.8 based on the latest data in our nightly-refreshed cache.
How fast is Envista Holdings Corporation growing?
NVST's revenue grew at roughly 7.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Envista Holdings Corporation have?
As of fiscal year 2025, NVST carried roughly $1.45B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Envista Holdings Corporation's gross margin?
NVST's gross margin was 54.7% in fiscal 2025 — gross profit of $1.49B on revenue of $2.72B.
What is Envista Holdings Corporation's market cap?
Envista Holdings Corporation (NVST) has a market capitalization of about $3.93B, based on the latest data in our nightly-refreshed cache.
When does Envista Holdings Corporation's fiscal year end?
NVST's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into NVST stock?
At today's market cap of $3.93B, Envista Holdings Corporation is priced for free-cash-flow growth of about 5.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $230.40M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.5%/yr over the last five fiscal years and revenue 7.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Envista Holdings Corporation's official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.